Recombinant Human LIGHT/TNFSF14 Protein

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS?CoV and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 .The RBD of SARS-CoV-2 binds a metallopeptidase, angiotensin-converting enzyme 2 (ACE-2). Before binding to the ACE-2 receptor, structural analysis of the S1 trimer shows that only one of the three RBD domains is in the "up" conformation. This is an unstable and transient state that passes between trimeric subunits but is nevertheless an exposed state to be targeted for neutralizing antibody therapy. Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE-2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy.  （CDNF）也是一種新型神經(jīng)營(yíng)養(yǎng)因子，對(duì)多巴胺能神經(jīng)元的強(qiáng)大活性，與神經(jīng)膠質(zhì)細(xì)胞系衍生的（GDNF）相當(dāng)。Recombinant Human LIGHT/TNFSF14 Protein,hFc Tag

Recombinant Biotinylated Human MSLN/Mesothelin Protein,hFc-Avi Tag分子別名（Synonyms）Mesothelin;CAK1;MSLN;MPFSMRP表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）BiotinylatedHumanMSLN/MesothelinProteinisexpressedfromHEK293withhFctagandAvitagattheC-Terminus.ItcontainsGlu296-Gly580.[Accession|Q13421-2]分子量大?。∕olecularWeight）TheproteinhasapredictedMWof61.1kDa.Duetoglycosylation,theproteinmigratesto70-80kDabasedonSDS-PAGEresult.（Endotoxin）Lessthan1EUperμgbytheLALmethod.純度（Purity）>95%asdeterminedbySDS-PAGEandHPLC.活性（Activity）ELISAData:ImmobilizedAnti-MSLNAntibody,hFcTagat1μg/ml(100μl/well)ontheplate.DoseresponsecurveforBiotinylatedHumanMSLN,hFcTagwiththeEC50of18.4ng/mldeterminedbyELISA.Recombinant Human IgG1 Fc Protein,Tag TagFractalkine，指定為CX3CL1，與大多數(shù)其他趨化因子不同，CX3CL1是I型跨膜（TM）粘附蛋白。

α-凝血酶（α-Thrombin）產(chǎn)品性質(zhì)中文別名（Chinesesynonym）α-凝血酶；IIa因子；英文別名（Englishsynonym）α-Thrombin；FactorIIaCAS號(hào)（CASNO.）9002-04-4分子量（Molecularweight）37000daltons活力（Activity）≥3091.00NIHU/mg緩沖液組分（Buffer）50mMSodiumCitrate/0.2MNaCl/0.1%PEG-8000/pH6.5含量（Totalprotein）0.324mg運(yùn)輸和保存方法粉末冰袋運(yùn)輸，2-8℃保存；配好的液體，請(qǐng)于≤-60℃保存。使用方法（酶切體系）產(chǎn)品溶于水，配成的1000U/ml儲(chǔ)存液，根據(jù)使用量分配于不同的離心管中，凍存于?20℃保存，凝血酶對(duì)不同的融合蛋白切割效率是不一樣的，首先要進(jìn)行小量切割試驗(yàn)。比如固定融合蛋白10ug，加不同量的凝血酶（如0.1U,0.2U,0.5U,1U等),在不同的溫度(如4度,16度,室溫或37度等)下進(jìn)行試驗(yàn)。

Dabigatranetexilatemesylate，又稱甲磺酸達(dá)比加群酯，是可口服的凝血酶抑制劑，是一種抗凝藥，通過(guò)競(jìng)爭(zhēng)結(jié)合凝血酶的纖維蛋白特異結(jié)合位點(diǎn)，阻礙纖維蛋白生成，從而抑制血栓的形成。產(chǎn)品信息英文別名(EnglishSynonym)Dabigatranetexilatemesylate,Pradaxa,BIBR1048MS,Dabigatranetexilatemethanesulfonate中文名稱(ChineseName)甲磺酸達(dá)比加群酯，達(dá)比加群酯甲磺酸鹽靶點(diǎn)(Target)Thrombin通路(Pathway)Protease/MetabolicEnzyme--ThrombinCAS號(hào)(CASNO.)872728-81-9分子式(Formula)C35H45N7O8S分子量(MolecularWeight)723.84外觀(Appearance)粉末純度(Purity)≥98%溶解性(Solubility)溶于DMSO運(yùn)輸和保存方法-25~-15℃保存，有效期3年。使用方法【數(shù)據(jù)來(lái)自于公開(kāi)發(fā)表的文獻(xiàn)，供參考，具體使用濃度請(qǐng)參考相關(guān)文獻(xiàn)，并根據(jù)自身實(shí)驗(yàn)條件（如實(shí)驗(yàn)?zāi)康?，?xì)胞種類，培養(yǎng)特性等）進(jìn)行摸索和優(yōu)化?！縿?dòng)物實(shí)驗(yàn)（體內(nèi)實(shí)驗(yàn)）在體內(nèi)，口服dabigatranetexilate在大10-50mg/kg)和恒河猴(1-5mg/kg)時(shí)間劑量依賴性地表現(xiàn)出抗凝效果。然而，在肝臟中，IL-28A誘導(dǎo)的Th1細(xì)胞因子反應(yīng)有助于T細(xì)胞介導(dǎo)的肝炎的炎癥。

Recombinant Biotinylated Human HBV (HLA-A*02:01) Protein,His-Avi Tag性能參數(shù)表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）RecombinantBiotinylatedHumanHBV(HLA-A*02:01)ProteinisexpressedfromHEK293withHistagandAvitagattheC-terminalItcontainsGly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M)andFLLTRILTIpeptide.[Accession|A0A140T913(HLA-A*02:01)&P61769(B2M)&FLLTRILTIpeptide]分子量大?。∕olecularWeight）TheproteinhasapredictedMWof50.5kDa.Duetoglycosylation,theproteinmigratesto52-62kDabasedonTris-BisPAGEresult.（Endotoxin）Lessthan1EUperμgbytheLALmethod.純度（Purity）>95%asdeterminedby>95%asdeterminedbyHPLC制劑（Formulation）Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法（Reconstitution）Centrifugetubesbeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.泛素化反應(yīng)可以修飾蛋白質(zhì)，調(diào)節(jié)蛋白質(zhì)降解。泛素化還影響蛋白質(zhì)體事件，如蛋白質(zhì)定位、活性和功能。Recombinant Mouse LOX1 Protein,His Tag

IdeS 具有獨(dú)特的底物選擇性，可以作為工具酶應(yīng)用于抗體類藥物或抗體融合蛋白藥物的結(jié)構(gòu)表征分析。Recombinant Human LIGHT/TNFSF14 Protein,hFc Tag

CD30,又稱KI抗原和Tnfrsf8,是一種120kdaI型跨膜糖蛋白,屬于tnf受體超家族。成熟的人CD30由一個(gè)361AA細(xì)胞外域(ECD)和六個(gè)富含半胱氨酸的重復(fù),28AA跨膜段和188AA細(xì)胞質(zhì)域。相比之下,小鼠和大鼠CD30缺乏90AA的ECD,并且只包含三個(gè)富含半胱氨酸的重復(fù)。在ECD的共同區(qū)域內(nèi),人CD30與小鼠CD30和大鼠CD30的序列認(rèn)同率分別為53%和49%。人類CD30的交替剪接產(chǎn)生一個(gè)等形,包括細(xì)胞質(zhì)域的C132AA。CD30通常在抗原細(xì)胞和B細(xì)胞上表達(dá)。但是,它在霍奇金氏病(紅-斯特恩伯格細(xì)胞上)、其他淋巴瘤、慢性炎癥中,以及自體免疫。CD30與CD30配體/tnfsf8結(jié)合,TH細(xì)胞、單核細(xì)胞、粒細(xì)胞和髓質(zhì)胸腺上皮細(xì)胞上表達(dá)。產(chǎn)品性質(zhì)別名CD30;CD30KI-1;CD30Lreceptor;TNFRSF8;D1S166EKi-1;CD30KI-1工會(huì)編號(hào)P28908-1表達(dá)區(qū)間及表達(dá)系統(tǒng)重組的人CD30/Tnfrsf8蛋白表達(dá)于在C-端有標(biāo)記和AVI標(biāo)記的HK293細(xì)胞。它含有……。分子量大約41.3公里。由于糖基化,蛋白質(zhì)遷移到70-100kda基于三聯(lián)頁(yè)面結(jié)果。純度SDS-PAGE和高效液相色譜法測(cè)定的95%。Recombinant Human LIGHT/TNFSF14 Protein,hFc Tag